title: [Effect of furosemide on the plasma level of atrial natriuretic peptide (ANP) in healthy persons and in patients with uncomplicated primary arterial hypertension].
abstract: The study included 15 healthy individuals aged 37.3 +/- 7.7 years and 27 patients with the primary uncomplicated blood hypertension (stages I and II according to WHO classification) of the comparable age, untreated and given a diet containing 100-120 nM Na+ daily. Plasma ANP concentrations were measured prior to and after 30, 60, and 90 minutes following 40 mg furosemide intravenously. An increase in 1-minute urine output and 1-minute Na+ excretion in the urine were determined during 90 minutes following furosemide administration. A significant decrease in ANP plasma levels was noted in all examined individuals following furosemide administration in all time intervals comparing with baseline values. An increase in 1-minute urine output and 1-minute sodium excretion with the urine significantly correlated with plasma ANP decrease during 90 minutes following furosemide administration. The obtained results suggest that furosemide inhibits ANP secretion in the patients with uncomplicated primary hypertension similarly to healthy individuals.
authors.forename: S
authors.initials: S
authors.lastname: Czekalski
authors.forename: K
authors.initials: K
authors.lastname: Widecka
authors.forename: J
authors.initials: J
authors.lastname: Goździk
mesh_terms: D000328:Adult; D009320:Atrial Natriuretic Factor / Q000037:antagonists & inhibitors / Q000097:blood* / Q000187:drug effects; D003864:Depression, Chemical; D004231:Diuresis / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005665:Furosemide / Q000008:administration & dosage*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012016:Reference Values
chemical_list: D005665:Furosemide; D009320:Atrial Natriuretic Factor
vernacular_title: Wpływ furosemidu na stezenie przedsionkowego peptydu natriuretycznego (ANP) w osoczu osób zdrowych i chorych na niepowikłane pierwotne nadciśnienie tetnicze.